WO2003004603A3 - Procedes de modulation de la pharmacocinetique des oligonucleotides - Google Patents

Procedes de modulation de la pharmacocinetique des oligonucleotides Download PDF

Info

Publication number
WO2003004603A3
WO2003004603A3 PCT/US2002/020940 US0220940W WO03004603A3 WO 2003004603 A3 WO2003004603 A3 WO 2003004603A3 US 0220940 W US0220940 W US 0220940W WO 03004603 A3 WO03004603 A3 WO 03004603A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
methods
moe
modified oligonucleotides
modulating pharmacokinetics
Prior art date
Application number
PCT/US2002/020940
Other languages
English (en)
Other versions
WO2003004603A2 (fr
Inventor
Thazha P Prakash
Muthiah Manoharan
Original Assignee
Isis Pharmaceuticals Inc
Thazha P Prakash
Muthiah Manoharan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/058,740 external-priority patent/US6921812B1/en
Application filed by Isis Pharmaceuticals Inc, Thazha P Prakash, Muthiah Manoharan filed Critical Isis Pharmaceuticals Inc
Priority to EP02742381A priority Critical patent/EP1409731A2/fr
Priority to CA002452310A priority patent/CA2452310A1/fr
Publication of WO2003004603A2 publication Critical patent/WO2003004603A2/fr
Publication of WO2003004603A3 publication Critical patent/WO2003004603A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On a incorporé du 2'-O-(2-Méthylthioéthyle) dans des oligonucléotides et on a évalué leurs propriétés antisens par comparaison avec la modification connue du 2'-O-(2-méthoxyéthyle)2'-O-MOE. Les oligonucléotides modifiés 2'-O-MTE présentent une liaison améliorée à la sérum-albumine humaine comparativement aux oligonucléotides modifiés 2'-O-MOE et conservent une forte affinité de liaison pour l'ARN cible.
PCT/US2002/020940 2001-07-03 2002-07-01 Procedes de modulation de la pharmacocinetique des oligonucleotides WO2003004603A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02742381A EP1409731A2 (fr) 2001-07-03 2002-07-01 Procedes de modulation de la pharmacocinetique des oligonucleotides
CA002452310A CA2452310A1 (fr) 2001-07-03 2002-07-01 Procedes de modulation de la pharmacocinetique des oligonucleotides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30268301P 2001-07-03 2001-07-03
US60/302,683 2001-07-03
US10/058,740 US6921812B1 (en) 2001-07-03 2002-01-28 Methods of modulating pharmacokinetics of oligonucleotides
US10/058,740 2002-01-28

Publications (2)

Publication Number Publication Date
WO2003004603A2 WO2003004603A2 (fr) 2003-01-16
WO2003004603A3 true WO2003004603A3 (fr) 2003-12-04

Family

ID=26737983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/020940 WO2003004603A2 (fr) 2001-07-03 2002-07-01 Procedes de modulation de la pharmacocinetique des oligonucleotides

Country Status (3)

Country Link
EP (1) EP1409731A2 (fr)
CA (1) CA2452310A1 (fr)
WO (1) WO2003004603A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947817B2 (en) 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
FR2860143B1 (fr) * 2003-09-26 2008-06-27 Oreal Composition cosmetique comprenant un polymere sequence et une huile siliconee non volatile
US7928207B2 (en) * 2004-06-28 2011-04-19 Roche Molecular Systems, Inc Synthesis and compositions of nucleic acids comprising 2′-terminator nucleotides
US7745125B2 (en) 2004-06-28 2010-06-29 Roche Molecular Systems, Inc. 2′-terminator related pyrophosphorolysis activated polymerization
EP2891717B1 (fr) 2012-08-31 2020-04-29 Kyowa Kirin Co., Ltd. Oligonucléotide
EP3130597B1 (fr) * 2014-03-03 2021-11-10 Kyowa Kirin Co., Ltd. Oligonucléotide ayant un nucléotide non-naturel a l'extrémité 5'
US11518780B2 (en) 2019-07-31 2022-12-06 Shiyue Fang Sensitive oligonucleotide synthesis using sulfur-based functions as protecting groups and linkers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6239272B1 (en) * 1995-04-20 2001-05-29 Ribozyme Pharmaceutical 2'-O-alkylthioalkyl and 2'-c-alkylthioalkyl-containing nucleic acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239272B1 (en) * 1995-04-20 2001-05-29 Ribozyme Pharmaceutical 2'-O-alkylthioalkyl and 2'-c-alkylthioalkyl-containing nucleic acids
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRAKASH T. ET AL.: "2'-O-(2-(methylthio)ethyl)-modified oligonucleotide: An analogue of 2'-O-(2-(methoxy)ethyl)-modified oligonucleotide with improved protein binding properties and high binding affinity to target RNA", BIOCHEMISTRY, vol. 41, September 2002 (2002-09-01), pages 11642 - 11648, XP002962878 *

Also Published As

Publication number Publication date
CA2452310A1 (fr) 2003-01-16
EP1409731A2 (fr) 2004-04-21
WO2003004603A2 (fr) 2003-01-16

Similar Documents

Publication Publication Date Title
CA2383926A1 (fr) Genomique fonctionnelle utilisant des proteines a doigts de zinc
EP2292771A3 (fr) Thérapie à base d'ARNm sens
AU2001241413A1 (en) Nucleic acids, proteins, and antibodies
AU2001274888A1 (en) Nucleic acids, proteins, and antibodies
EP1862472A3 (fr) Protéine de Chlamydia, séquence génétique et utilisations associées
EP2330129A3 (fr) Anticorps anti-TNF, compositions, procédés et utilisations
WO2001070977A3 (fr) Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
WO2001061007A3 (fr) Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants
WO2003004603A3 (fr) Procedes de modulation de la pharmacocinetique des oligonucleotides
AU2002228805A1 (en) Antisense modulation of damage-specific dna binding protein 2, p48 expression
WO2002062954A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-beta
AU2001296301A1 (en) Nucleic acids, proteins, and antibodies
WO2005005632A3 (fr) PETITS ARN INTERFERENTS SPECIFIQUES DES SOUS-UNITES α, α' ET β DE LA PROTEINE KINASE CK2 ET LEURS APPLICATIONS
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2001294833A1 (en) Chlamydia pmp proteins, gene sequences and uses thereof
EP1248635A4 (fr) Modulation antisens d'expression de la glycogene synthase kinase 3 alpha
WO2001002429A3 (fr) Angiopoietine 6 et ses utilisations
AU2002365925A1 (en) Rsv proteins, antibodies, compositions, methods and uses
AU2001297698A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2002350599A1 (en) Homeotic genes and proteins, and uses thereof
WO2002055659A3 (fr) Modulation antisens de l'expression de la proteine de liaison a l'integrine beta-4
WO2003009836A3 (fr) Nouvelles utilisations de 2-amino-2-propane-1,3-diols
AU2001292755A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002020716A3 (fr) Modulation antisens de l'expression de la phosphorylase kinase alpha 2
WO2002034901A3 (fr) Proteine kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2452310

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002742381

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002315517

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002742381

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002742381

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP